Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Sage Therapeutics' CFO to leave, drugmaker to lay off over 165 employees
Sage Therapeutics said on Thursday its finance chief will leave the company and the drugmaker plans to lay off more than 165 employees as part of a reorganization plan that aims to focus on the launch of its postpartum depression pill.
Sage Therapeutics to lay off one-third of workforce
After a year of disappointing drug trial results, Sage Therapeutics Inc. is slashing its headcount and shaking up its leadership team.
After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce
Sage Therapeutics announces reorganization, including layoffs and pipeline changes, to support the launch of Zurzuvae. Focus shifts to Huntington's Disease trial after setbacks in essential tremor and Alzheimer's treatments.
Sage Therapeutics to lay off more than 165 employees
Sage Therapeutics said on Thursday it will lay off more than 165 employees or about 33% of the company's total workforce.
Sage Therapeutics to lay off one-third staff under reorganization
Sage Therapeutics (NASDAQ:SAGE) announced a reorganization, including a workforce reduction of about 33%, to support the ongoing launch of ZURZUVAE for postpartum depression and to focus on pipeline development ahead of a clinical readout for dalzanemdor in Huntington’s Disease expected later this year.
17h
on MSN
Sage Therapeutics’ stock falls 4.7% as biotech unveils plan to cut 33% of workforce
Sage Therapeutics Inc.’s stock slid 4.7% Thursday, after the biotech said it’s cutting about 33% of its workforce as part of ...
pharmaphorum
8h
Sage cuts a third of its workforce after R&D setbacks
Sage said in an SEC filing that it expects a non-recurring charge tied to the workforce reduction of $26 million to $28 ...
FierceBiotech
1d
Sage lays off half of R&D team, shakes up C-suite again
Sage Therapeutics’ latest attempt to shrink its pipeline and workforce will see a third of the biotech’s employees heading ...
The Pharma Letter
43m
Sage slashes further jobs as need to deliver deepens
US biotech company Sage Therapeutics is to slash a third of its remaining jobs - just a year after cutting 40% of its prior workforce.
9h
SAGE Therapeutics’ Strategic Reorganization and Cautious Hold Rating Amid Development Setbacks
Needham analyst Ami Fadia has reiterated their neutral stance on SAGE stock, giving a Hold rating on October 10. Ami Fadia’s rating is ...
1d
Sage Cuts One-Third of Workforce After Clinical Trial Setbacks
Sage Therapeutics Inc. is laying off more than 165 employees as the biotech company tries to conserve cash after multiple ...
BioPharma Dive
22h
Sage to cut one-third of workforce, streamline drug pipeline
The restructuring, which follows clinical setbacks in Alzheimer’s, Parkinson’s and tremor, will also involve the departure of five senior executives.
21h
Sage Therapeutics Cuts Workforce by 33% in Reorganization, Focuses on ZURZUVAE Launch and Pipeline
Several executives will depart as part of the changes, including Anne Marie Cook, Kimi Iguchi, Matt Lasmanis, Heinrich ...
1d
The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Sage Therapeutics Inc
The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Sage Therapeutics Inc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Research and development
ZURZUVAE
Feedback